



3401 Princeton Pike, Lawrenceville, NJ 08648

Notice Regarding Adjustment of 340B Prices for Select Products of Bristol Myers Squibb

December 22, 2021

Bristol Myers Squibb (BMS) has recalculated its 340B ceiling prices for the period from Q1 2019 through Q2 2020 for the products listed below due to revisions made to their Medicaid pricing data. BMS has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about BMS' recalculation affecting certain 340B Covered Entities for the impacted product(s).

BMS has determined the credit amount owed to each affected covered entity. BMS will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
59572-0215-13	THALOMID CAP 150MG (4BLPX7) US
59572-0215-93	THALOMID CAP 150MG (8BLPX14) US
59572-0984-01	ISTODAX LINJ 10MG 1VL W/2ML DIL US
59572-0720-12	INREBIC CAP 100MG (1BTLX120) US
59572-0710-30	IDHIFA TAB 100MG (1BTLX30) US
68817-0134-50	ABRAXANE LINJ 100MG (1VL) 50ML US

Q1 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020
59572021513	59572021513	59572072012	59572071030	59572098401
59572021593	59572021593	68817013450	59572098401	68817013450
59572071030			68817013450	

If a Covered Entity believes they are due a refund and are not contacted by Apexus by February 28, 2022, please contact Margarita.Womelsdorf@bms.com.